Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

FLUOCINOLONE
Trade names: Capex (Galderma); Synalar (Medicis)
Indications: Dermatoses, Asthma, Ophthalmology
Category: Corticosteroid, topical
Half-life: N/A
Clinically important, potentially hazardous interactions
with: live vaccines
Reactions
Skin
Adverse effects (sic)
Atrophy
Burning
Facial erythema
(1981): Tirlapur VG+, Br J Clin Pract 35(7-8), 275
Pigmentation
Pruritus
Rash (sic)
(1993): Hisa T+, Contact Dermatitis 28(3), 174
Rosacea
Sensitivity
(1983): Pasricha JS+, Contact Dermatitis 9(4), 330
Telangiectasia
(1981): Tirlapur VG+, Br J Clin Pract 35(7-8), 275
Thinning
(1984): Somerma S+, Acta Derm Venereol 64(1), 41
Ulcerative necrosis
Eyes
Cataract
(2006): Jaffe GJ+, Ophthalmology 113(6), 1020
(2005): Holekamp NM+, Am J Ophthalmol 139(3), 421
Glaucoma
(1995): Katsushima H, Nippon Ganka Gakkai Zasshi 99(2), 238
Intraocular pressure increased
(2006): Jaffe GJ+, Ophthalmology 113(6), 1020
Ocular pressure
(2005): Holekamp NM+, Am J Ophthalmol 139(3), 421
(2005): Jaffe GJ+, Ophthalmology 112(7), 1192
(2000): Jaffe GJ+, Ophthalmology 107(11), 2024
Retinitis
(2007): Ufret-Vincenty RL+, Am J Ophthalmol 143(2), 334
Other
Infections
Side effects (sic)
(1985): Jegasothy B+, Int J Dermatol 24(7), 461
FLUOCINONIDE
Trade names: Fluonex; Lidex (Medicis); Lonide; Topsyn
Indications: Dermatoses
Category: Corticosteroid, topical
Half-life: N/A
Clinically important, potentially hazardous interactions
with: live vaccines
Skin
Acne
Adverse effects (sic)
Reactions
(1994): Bruce S+, JAmAcadDermatol31(5), 755
(1985): Jegasothy B+, Int J Dermatol 24(7), 461 (12%)
Burning
Dermatitis
(1999): Miura Y+, Contact Dermatitis 41(2), 118
(1993): Hisa T+, Contact Dermatitis 28, 174
Erythema
Pigmentation
Pruritus
(1996): Carbone M+, Minerva Stomatol 45(3), 61
Rash (sic)
Rosacea
Xerosis
Mucosal
Mucosal bleeding
(1996): Carbone M+, Minerva Stomatol 45(3), 61
Eyes
Keratopathy
(2005): Savage HI+, Cornea 24(3), 342 (with ketoconazole)
Other
Infections
FLUORIDES
Trade names: Acidulated phosphate fluoride; F;
Fluorophosphate; Hydrogen fluoride [HF]; Monofluorophosphate
[MFP]; Silicofluoride; Sodium fluoride [NaF]; Sodium
monofluorophosphate; Stannous fluoride [SF]; Sulfur hexafluoride
[SF6]
Indications: Caries prevention (topical), osteoporosis prevention
(oral)
Category: Chemical
Half-life: N/A
Clinically important, potentially hazardous interactions
with: caffeine
Reactions
FLUORIDES 229
Skin
Acne
Atopic dermatitis
Burning
(2002): Fujimoto K+, J Nippon Med Sch 69(2), 180 (HF)
(1995): Saada V+, Ann Dermatol Venereol 122(8), 512 (HF)
(1993): Bordelon BM+, JTrauma34(3), 437 (HF)
(1992): Mistry DG+, Am Fam Physician 45(4), 1748 (HF)
(1988): MacKinnon MA, Dermatol Clin 6(1), 67 (HF)
(1987): Modly CE+, Cutis 40(2), 89
(1987): Mullett T+, J Burn Care Rehabil 8(3), 216 (HF) (fatal)
(1986): Edelman P, Occup Med 1(1), 89 (HF)
(1986): Vance MV+, Ann Emerg Med 15(8), 890 (HF)
(1985): Mayer TG+, Ann Emerg Med 14(2), 149 (HF)
(1980): Tepperman PB, J Occup Med 22(10), 691 (HF)
Calcification
Carcinoma
(1996): Tohyama E, JEpidemiol6(4), 184 (uterine)
Dermatitis
(2003): McCaffery K, J Am Dent Assoc 134(9), 1166
(1997): Ganter G+, Contact Dermatitis 37(5), 248
(1993): Isaksson M+, Scand J Dent Res 101(1), 49 (Duraphat)
Dermatitis herpetiformis
(1985): Bovenmyer DA, JAmAcadDermatol12(4), 719
(aggravataion)